UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Commission File Number: 001-40489 VERVE THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) (State or oth ...

1 | --- | --- | --- | |-------|---------------------------------------------------------------------------------------------|-------| | | | | | | | | | | | | | | | | | | | | | | Verve Therapeutics | | | | Disrupting the Care of Cardiovascular Disease Through Single-course Gene Editing Medicines | | | | August 2023 | | Forward looking statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR 201 Brookline Avenue, Suite 601 Boston, Massachusetts 02215 (Address of principal executive offices) (Zip Code) Delaware 82-4800132 (I.R.S. Employer Identification No.) Registrant's telephone number, including area code: (617) 603-0070 Securities registered pursuant to Section 12(b) ...

1 | --- | --- | |-------|----------------------------------------------------------------------------------------------| | | | | | Developing 'once-and-done' | | | gene editing medicines to treat cardiovascular disease | | | Sekar Kathiresan, MD CEO, Verve Therapeutics Lecturer in Medicine, Harvard Medical School | | | May 8, 2023 TIDES USA: Oligonucleotide and peptide therapeutics | Atherosclerotic cardiovascular disease (ASCVD): #1 cause of death worldwide despite available treatments One person dies ever ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 VERVE THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) (State or other jurisdiction of incorporation or organization) 201 Brookline Avenue, Suite 601 Boston, Massachusetts 02215 (Address of principal executive offices) (Zip Code) Delaware 82-4800132 (I.R.S. Employer Identification No.) For the quarterly p ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40489 VERVE THERAPEUTICS, INC. (Exact name of Registrant as specified in its Charter) Delaware 82-4800132 (State or other jurisdictio ...

1 Verve Therapeutics Disrupting the Care of Cardiovascular Disease Through Single-course Gene Editing Medicines January 2023 Forward looking statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties, including statements regarding the timing and availability of clinical data from the Company's heart-1 clinical trial, the timing of initiation of clinical trials of VERVE-201, th ...

1 | --- | --- | |-------|-------------------------------------------------------------------------------| | | | | | VERVE-101 – an investigational singlecourse gene editing medicine targeting | | | PCSK9 – durably and potently lowers | | | PCSK9 and LDL-C concentrations in | | | non-human primates | | | Amit V. Khera MD, MSc Verve Therapeutics | | | Paul Dudley White International Scholar Awardee | Forward looking statements This press release contains "forward-looking statements" within the meaning of the ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Commission File Number: 001-40489 VERVE THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 82-4 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO 2SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Commission File Number: 001-40489 VERVE THERAPEUTICS , INC. (Exact Name of Registrant as Specified in its Charter) Delaware 82-4800 ...